Scribble acts as an oncogene in Eμ-myc-driven lymphoma

被引:0
|
作者
E D Hawkins
J Oliaro
K M Ramsbottom
A Newbold
P O Humbert
R W Johnstone
S M Russell
机构
[1] Cancer Immunology Program,Sir Peter MacCallum Department of Oncology
[2] Peter MacCallum Cancer Centre,Department of Pathology
[3] The University of Melbourne,Department of Biochemistry and Molecular Biology
[4] Melbourne,undefined
[5] Victoria,undefined
[6] Australia,undefined
[7] Cancer Therapeutics Programs,undefined
[8] Peter MacCallum Cancer Centre,undefined
[9] Cell Cycle and Cancer Genetics Laboratory,undefined
[10] Peter MacCallum Cancer Centre,undefined
[11] The University of Melbourne,undefined
[12] Melbourne,undefined
[13] Victoria,undefined
[14] Australia,undefined
[15] The University of Melbourne,undefined
[16] Melbourne,undefined
[17] Victoria,undefined
[18] Cell cycle and Cancer Genetics Laboratory,undefined
[19] Peter MacCallum Cancer Centre,undefined
[20] Centre for Micro-Photonics,undefined
[21] Swinburne University of Technology,undefined
[22] 9Current address: Imperial College London,undefined
[23] Sir Alexander Fleming Building,undefined
[24] SW72AZ,undefined
[25] London,undefined
[26] UK.,undefined
来源
Oncogene | 2016年 / 35卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Scribble complex proteins maintain apicobasal polarity, regulate cell fate determination and function as tumour suppressors in epithelial tissue. Despite evidence that the function of Scribble is maintained in the lymphocyte lineage, we still understand little about its role as a tumour suppressor in haematological malignancies. Using the Eμ-myc model of Burkitt’s lymphoma we investigated the role of Scribble in lymphomagenesis. We found that contrary to its well-documented tumour suppressor role in epithelial tissue, loss of Scribble expression delayed the expansion of peripheral B cells and delayed the onset of Eμ-myc-driven lymphoma. This was despite upregulated ERK phosphorylation levels in Scribble-deficient tumours, which are associated with loss of Scribble expression and the development of more aggressive Burkitt’s lymphoma. Interestingly, the developmental stage of lymphoma was unaffected by Scribble expression challenging any role for Scribble in fate determination in the haematopoetic lineage. These data provide evidence for oncogenic properties of Scribble in Myc-driven B-cell lymphomagenesis, reinforcing recent findings that overexpression of a mutant form of Scribble can act as an oncogene in epithelial cells. Our results support the growing appreciation that the tumour regulatory functions of Scribble, and other polarity protein family members, are context dependent.
引用
收藏
页码:1193 / 1197
页数:4
相关论文
共 50 条
  • [1] Scribble acts as an oncogene in Eμ-myc-driven lymphoma
    Hawkins, E. D.
    Oliaro, J.
    Ramsbottom, K. M.
    Newbold, A.
    Humbert, P. O.
    Johnstone, R. W.
    Russell, S. M.
    ONCOGENE, 2016, 35 (09) : 1193 - 1197
  • [2] Targeting nucleotide synthesis in MYC-driven lymphoma
    Gemma K. Alderton
    Nature Reviews Cancer, 2014, 14 (7) : 452 - 452
  • [3] IBTK Haploinsufficiency Affects the Tumor Microenvironment of Myc-Driven Lymphoma in E-myc Mice
    Vecchio, Eleonora
    Fiume, Giuseppe
    Mignogna, Chiara
    Iaccino, Enrico
    Mimmi, Selena
    Maisano, Domenico
    Trapasso, Francesco
    Quinto, Ileana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [4] Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma
    Zhang, Xuan
    Bi, Chengfeng
    Lu, Ting
    Yue, Ting
    Zhang, Weiwei
    Zhang, Xiaoyan
    Cheng, Wang
    Tian, Tian
    Lunning, Matthew A.
    Vose, Julie M.
    Pelletier, Jerry
    Porco, John A., Jr.
    Tao, Jianguo
    Fu, Kai
    BLOOD, 2018, 132
  • [5] Synthetic lethal targeting of SUMOylation in Myc-driven lymphoma
    Hoellein, A.
    Fallahi, M.
    Schaub, F.
    Schoeffmann, S.
    Steidle, S.
    Rudelius, M.
    Miething, C.
    Peschel, C.
    Cleveland, J.
    Keller, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 11 - 11
  • [6] MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma
    Xu-Monette, Zijun Y.
    Manyam, Ganiraju C.
    Tzankov, Alexander
    Deng, Qipan
    Visco, Carlo
    Tu, Meifeng
    Li, Ling
    Zu, Youli
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    van Krieken, J. Han
    Huh, Jooryung
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Moller, Michael B.
    Farnen, John P.
    Zhao, Xiaoying
    Piris, Miguel A.
    Winter, Jane N.
    Miranda, Roberto N.
    McDonnell, Timothy J.
    Medeiros, L. Jeffrey
    Li, Yong
    Young, Ken H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S223 - S223
  • [7] Targeting MYC-driven lymphoma: lessons learned and future directions
    Martinez-Martin, Sandra
    Beaulieu, Marie-Eve
    Soucek, Laura
    CANCER DRUG RESISTANCE, 2023, 6 (02) : 205 - 222
  • [8] An MYC-Driven Vicious Circuit Is a Targetable Achilles' Heel in Lymphoma
    Wilson, Erica B.
    Klein, Ulf
    BLOOD CANCER DISCOVERY, 2023, 4 (04): : 248 - 251
  • [9] BCR LOSS REDUCES THE FITNESS OF MYC-DRIVEN LYMPHOMA CELLS
    不详
    CANCER DISCOVERY, 2017, 7 (07) : 664 - 664
  • [10] Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
    Ferrao, P. T.
    Bukczynska, E. P.
    Johnstone, R. W.
    McArthur, G. A.
    ONCOGENE, 2012, 31 (13) : 1661 - 1672